IMVT
Immunovant IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.01B
P/E Ratio
—
EPS
$-2.64
Beta
0.67
52W High
$29.25
52W Low
$13.36
50-Day MA
$25.76
200-Day MA
$21.22
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immunovant Inc
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-486.75M |
| Operating Margin | 0.00% |
| Return on Equity | -69.40% |
| Return on Assets | -41.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.85 |
| Price-to-Book | 5.06 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -14.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $203.53M |
| Float | $77.47M |
| % Insiders | 57.04% |
| % Institutions | 54.22% |
Analyst Ratings
Consensus ($40.12 target)
2
Strong Buy11
Buy5
HoldData last updated: 4/8/2026